Title |
Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)–CC genotype caused by pegylated interferon (IFN)-α-2a with ribavirin therapy: a case report
|
---|---|
Published in |
BMC Research Notes, March 2014
|
DOI | 10.1186/1756-0500-7-141 |
Pubmed ID | |
Authors |
Weimin Jiang, Hisashi Hidaka, Takahide Nakazawa, Hiroyuki Kitagawa, Wasaburo Koizumi |
Abstract |
Pegylated interferon combined with ribavirin treatment is an effective therapy for chronic hepatitis C viral infection. However, pegylated interferon combined with ribavirin is associated with various adverse reactions. Severe thrombocytopenia is a life-threatening side effect of interferon therapy that can lead to bleeding. It is generally understood that the inosine triphosphatase-CC genotype does not have a significantly lower reduction by pegylated interferon combined with ribavirin in the mean platelet counts compared with the AA/CA genotype. We report a case of severe thrombocytopenia that developed in a patient with chronic hepatitis C treated with pegylated interferon combined with ribavirin in spite of having the inosine triphosphatase-CC genotype. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 4 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 1 | 25% |
Student > Postgraduate | 1 | 25% |
Student > Master | 1 | 25% |
Unknown | 1 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 2 | 50% |
Agricultural and Biological Sciences | 1 | 25% |
Unknown | 1 | 25% |